Caffeine as a preventive drug for Parkinson's disease: Epidemiologic evidence and experimental support;La cafeína como un fármaco preventivo de la enfermedad de Parkinson: Evidencias epidemiológicas y sustrato experimental

Revista de Neurologia

Volumn 50, Issue 4, 2010, Pages 221-229

  Góngora Alfaro, José Luis ^a  

^a UNIVERSIDAD AUTÓNOMA DE YUCATÁN   (Mexico)

Author keywords

Aging; Basal ganglia; Dopaminergic neuron; Methylxanthines; Neurodegeneration; Neuroprotection

Indexed keywords

CAFFEINE; HALOPERIDOL; OXIDOPAMINE; CENTRAL STIMULANT AGENT; DOPAMINE;

AGING; BASAL GANGLION; CATALEPSY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; ESTROGEN THERAPY; HUMAN; MENOPAUSE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; REVIEW; AGED; ANIMAL; ARTICLE; CHEMISTRY; COFFEE; DISEASE MODEL; DRUG EFFECT; FEMALE; MALE; METABOLISM; MIDDLE AGED; NERVE CELL; PATHOLOGY; RAT;

AGED; AGED, 80 AND OVER; ANIMALS; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; COFFEE; DISEASE MODELS, ANIMAL; DOPAMINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEURONS; PARKINSON DISEASE; RATS;

EID: 77949530340     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5004.2009563     Document Type: Review

References (40)

1. Ravina BM, Fagan SC, Hart RG, Hovinga CA, Murphy DD, Dawson TM, et al. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology 2003; 60: 1234-40.
2. Schapira AH, Olanow CW. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA 2004; 291: 358-64.
3. Linazasoro G, Sesar A, Valldeoriola F, Compta Y, Herrero MT, Martínez-Castrillo JC, et al. Neuroprotección en la enfermedad de Parkinson: análisis a través de la metodología de informadores clave. Neurologia 2009; 24: 113-24.
4. Instituto Nacional de Estadística, Geografía e Informática de México (INEGI). URL: http://www.inegi.org.mx. [31.08.2009].
5. Instituto Nacional de Estadística de España (INE). URL: http://www.ine.es. [31.08.2009].
6. Birkmayer W, Danielczyk W. La enfermedad de Parkinson. Barcelona: Herder; 1997.
7. Chou KL, Hurtig HI. Classical motor features of Parkinson's disease. In Ebadi M, Pfeiffer RF, eds. Parkinson's disease. Boca Raton FL: CRC Press; 2005. p. 171-81.
8. Weintraub D, Comella CL, Horn S. Parkinson's disease. Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment. Am J Manag Care 2008; 14 (Suppl): S40-8.
9. Lökk J. Caregiver strain in Parkinson's disease and the impact of disease duration. Eur J Phys Rehabil Med 2008; 44: 39-45.
10. Fahn S. Medical treatment of Parkinson's disease. J Neurol 1998; 245 (Suppl 3): S15-24.
11. Martignoni E, Riboldazzi G, Calandrella D, Riva N. Motor complications of Parkinson's disease. Neurol Sci 2003; 24 (Suppl 1): S27-9.
12. Lindgren P, Von Campenhausen S, Spottke E, Siebert U, Dodel R. Cost of Parkinson's disease in Europe. Eur J Neurol 2005; 12 (Suppl 1): S68-73.
13. Abasolo-Osinaga E, Abecia-Inchaurregui LC, Fernández-Díaz E, Barcenilla-Laguna A, Bañares-Onraita T. Prevalencia y coste farmacológico de la enfermedad de Parkinson en España. Rev Neurol 2006; 43: 641-5.
14. Cubo E, Martínez-Martín P, González M, Frades B, y miembros del grupo ELEP. Impacto de los síntomas motores y no motores en los costes directos de la enfermedad de Parkinson. Neurologia 2009; 24: 15-23.
15. Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 1999; 51: 83-133.
16. Hernán MA, Takkouche B, Caamaño-Isorna F, Gestal-Otero JJ. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 2002; 52: 276-84.
17. Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung KH, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 2000; 283: 2674-9.
18. Ascherio A, Zhang SM, Hernán MA, Kawachi I, Colditz GA, Speizer FE, et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 2001; 50: 56-63.
19. Ascherio A, Chen H, Schwarzschild MA, Zhang SM, Colditz GA, Speizer FE. Caffeine, postmenopausal estrogen, and risk of Parkinson's disease. Neurology 2003; 60: 790-5.
20. Ascherio A, Weisskopf MG, O'Reilly EJ, McCullough ML, Calle EE, Rodríguez C, et al. Coffee consumption, gender, and Parkinson's disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen. Am J Epidemiol 2004; 160: 977-84.
21. Hu G, Bidel S, Jousilahti P, Antikainen R, Tuomilehto J. Coffee and tea consumption and the risk of Parkinson's disease. Mov Disord 2007; 22: 2242-8.
22. Sääksjärvi K, Knekt P, Rissanen H, Laaksonen MA, Reunanen A, Männistö S. Prospective study of coffee consumption and risk of Parkinson's disease. Eur J Clin Nutr 2008; 62: 908-15.
23. Simon DK, Swearingen CJ, Hauser RA, Trugman JM, Aminoff MJ, Singer C, et al. Caffeine and progression of Parkinson disease. Clin Neuropharmacol 2008; 31: 189-96.
24. Kitagawa M, Houzen H, Tashiro K. Effects of caffeine on the freezing of gait in Parkinson's disease. Mov Disord 2007; 22: 710-2.
25. Kitagawa M, Houzen H, Tashiro K. Efectos de la cafeína sobre el fenómeno de congelación en la marcha de enfermos de Parkinson. I Encuentro Nacional de Expertos en Enfermedad de Parkinson. Rev Neurol 2008; 46 (Supl 2): S27.
26. Luquin MR. Modelos experimentales de enfermedad de Parkinson. Rev Neurol 2000; 31: 60-6.
27. Chen JF, Xu K, Petzer JP, Staal R, Xu YH, Beilstein M, et al. Neuroprotection by caffeine and A2A adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 2001; 21: RC143.
28. Xu K, Xu YH, Chen JF, Schwarzschild MA. Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice. Neurosci Lett 2002; 322: 13-6.
29. Joghataie MT, Roghani M, Negahdar F, Hashemi L. Protective effect of caffeine against neurodegeneration in a model of Parkinson's disease in rat: behavioral and histochemical evidence. Parkinsonism Relat Disord 2004; 10: 465-8.
30. Vasconcelos-Aguiar LM, Nobre HV Jr, Macêdo DS, Oliveira AA, Freitas RM, Vasconcelos SM, et al. Neuroprotective effects of caffeine in the model of 6-hydroxydopamine lesion in rats. Pharmacol Biochem Behav 2006; 84: 415-9.
31. Xu K, Xu Y, Brown-Jermyn D, Chen JF, Ascherio A, Dluzen DE, et al. Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine model of Parkinson's disease. J Neurosci 2006; 26: 535-41.
32. Ratner MH, Feldman RG. Environmental toxins and Parkinson's disease. In Ebadi M, Pfeiffer RF, eds. Parkinson's disease. Boca Raton FL: CRC Press; 2005. p. 51-62.
33. Bronstein J, Carvey P, Chen H, Cory-Slechta D, DiMonte D, Duda J, et al. Meeting report: consensus statement-Parkinson's disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) conference 26-28 June 2007. Environ Health Perspect 2009; 117: 117-21.
34. Hancock DB, Martin ER, Mayhew GM, Stajich JM, Jewett R, Stacy MA, et al. Pesticide exposure and risk of Parkinson's disease: a family-based case-control study. BMC Neurol 2008; 8: 6.
35. Costello S, Cockburn M, Bronstein J, Zhang X, Ritz B. Parkinson's disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California. Am J Epidemiol 2009; 169: 919-26.
36. Góngora-Alfaro JL, Moo-Puc RE, Villanueva-Toledo JR, Álvarez-Cervera FJ, Bata-García JL, Heredia-López FJ, et al. Long-lasting resistance to haloperidol-induced catalepsy in male rats chronically treated with caffeine. Neurosci Lett 2009; 463: 210-4.
37. Lorenc-Koci E, Wolfarth S, Ossowska K. Haloperidol-increased muscle tone in rats as a model of parkinsonian rigidity. Exp Brain Res 1996; 109: 268-76.
38. 3 receptor knock-out mice. Eur J Pharmacol 2000; 391: 63-73.
39. Álvarez-Cervera FJ, Villanueva-Toledo J, Moo-Puc RE, Heredia-López FJ, Álvarez-Cervera M, Pineda JC, et al. A novel automated rat catalepsy bar test system based on a RISC microcontroller. J Neurosci Methods 2005; 146: 76-83.
40. Carrillo JA, Benítez J. Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clin Pharmacokinet 2000; 39: 127-53.